Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $81.6667.

A number of analysts have weighed in on ARWR shares. Chardan Capital raised their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada boosted their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. The Goldman Sachs Group upped their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th.

Arrowhead Pharmaceuticals Stock Up 2.3%

Shares of NASDAQ:ARWR opened at $63.82 on Friday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $67.03 and a two-hundred day simple moving average of $45.26. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $76.76. The stock has a market capitalization of $8.94 billion, a price-to-earnings ratio of 41.71 and a beta of 1.21.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s revenue was up 10461.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.39) earnings per share. On average, research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares in the company, valued at $2,273,376. The trade was a 22.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the transaction, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 510,836 shares of company stock worth $33,603,060 in the last three months. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after buying an additional 510,798 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after acquiring an additional 300,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock valued at $216,799,000 after acquiring an additional 133,921 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after acquiring an additional 2,096,238 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after acquiring an additional 2,017,489 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.